Report LibraryAll Reports
Datamonitor Healthcare Oncology Disease Analysis: Hepatocellular Carcinoma (HCC)
July 14, 2021
Nexavar has been firmly established as the standard of care in advanced HCC since gaining approval in the US in 2007. However, Nexavar is forecast to steadily lose market share after the introduction of generics in 2020 (US), 2021 (EU), and 2022 (Japan). Additionally, Nexavar will face strong competition from the combination of Tecentriq + bevacizumab, which was the first regimen to demonstrate both superior overall survival (OS) and progression-free survival (PFS) over Nexavar, in the Phase III IMbrave150 study.
After demonstrating a PFS benefit and non-inferior OS to Nexavar in the Phase III REFLECT study, Lenvima became the second systemic therapy approved as a first-line treatment for HCC, in 2018. However, Lenvima is also expected to face significant competition from both the combination of Tecentriq + bevacizumab and from other immunotherapy regimens in development for the first-line setting. The loss of revenue to these therapies could be mitigated by approval of a Lenvima + Keytruda combination, which is currently being tested in the Phase III LEAP-002 trial.
This Datamonitor Healthcare report contains a Disease Analysis module.
|Indications Covered:||Hepatocellular (Liver) Cancer (HCC) (Including Secondary Metastases)|